MedPath

Pathogenesis of Intestinal Behcet's Syndrome

Recruiting
Conditions
Behcet's Syndrome, Intestinal Type
Interventions
Other: Biological samples collection
Registration Number
NCT06026020
Lead Sponsor
Peking Union Medical College Hospital
Brief Summary

There is a direct interaction between food, intestinal flora and the intestinal barrier composed of intestinal epithelial cells and mucosal immunity, whose composition and functional alterations are theorized to be closely related to the development of gastrointestinal (GI) involvement in Behcet's syndrome (BS) patients. Therefore, this study focuses on the population of patients with intestinal BS and explores the unique mechanisms leading to intestinal involvement in BS patients in terms of the characteristics of intestinal microecology. Since oral ulcers are one of the most common clinical manifestations in BS patients, in addition to intestinal flora analysis, this application project also plans to collect saliva samples from patients in the hope of obtaining a holistic understanding of mucosal flora in different parts of the entire GI tract. Serological testing and analysis will also be performed, focusing on changes in the intestinal tract and serum IgE levels, and analyzed in conjunction with microbiomics to provide evidence to further elucidate the pathogenesis of BS and GI involvement, and to search for more efficient therapeutic strategies, in terms of a variety of aspects, including clinical manifestations and disease progression.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
80
Inclusion Criteria

Behcet's syndrome patients with intestinal involvement:

  • Attendance at Peking Union Medical College Hospital, fulfillment of one of the two diagnostic criteria for BS (1990 Criteria of International Study Group for Behcet's disease or 2014 International Criteria for Behçet's Disease), and well-documented medical records;
  • Age 20-65 years old;
  • Have evidence of GI involvement, including clinical manifestations, laboratory tests, endoscopy, imaging and pathology;
  • Signed written informed consent and willingness to cooperate.

Behcet's syndrome patients with intestinal involvement:

  • Attendance at Peking Union Medical College Hospital, fulfillment of one of the two diagnostic criteria for BS (1990 Criteria of International Study Group for Behcet's disease or 2014 International Criteria for Behçet's Disease), and well-documented medical records;
  • Age 20-65 years old;
  • Have no evidence of GI involvement, including clinical manifestations, laboratory tests, endoscopy, imaging and pathology;
  • Signed written informed consent and willingness to cooperate.

Inflammatory bowel disease patients:

  • Attended Peking Union Medical College Hospital and was diagnosed with Crohn's disease by a combination of clinical, imaging, and pathologic diagnosis;
  • Age 20-65 years old;
  • Signed written informed consent and willingness to cooperate.

Health controls:

  • Healthy individuals aged 20-65 years;
  • Signed written informed consent and willingness to cooperate.
Exclusion Criteria
  • Other systemic diseases, such as autoimmune diseases, infectious diseases, malignant tumors, etc;
  • Patients with other intestinal diseases, such as intestinal tumors, intestinal tuberculosis, intestinal infections;
  • Patients with other oral diseases, such as cavity caries, oral abscesses, oral tumors, oral candidiasis, and dry mouth;
  • Patients taking antibiotics and probiotics within one month.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Behcet's syndrome patients with intestinal involvementBiological samples collection-
Health controlBiological samples collection-
Behcet's syndrome patients without intestinal involvementBiological samples collection-
Inflammatory bowel disease patientsBiological samples collection-
Primary Outcome Measures
NameTimeMethod
Structure and composition of metabolomicsDay 1 after addmission due to the disease activity and signing an informed consent (for patients); or day 1 after signing an informed consent (for health controls)

Serum extraction from blood samples will be tested through non-targeted metabolomics techniques to analysis and compare metabolomics among different groups.

Serum level of Immunoglobulin EDay 1 after addmission due to the disease activity and signing an informed consent (for patients); or day 1 after signing an informed consent (for health controls)

Serum extraction from blood samples will be used to test and compare the level of IgE among different groups.

Structure and composition of gut microbiotaDay 1 after addmission due to the disease activity and signing an informed consent (for patients); or day 1 after signing an informed consent (for health controls)

DNA extraction from stool samples will be tested through 16S microbial sequencing and metagenomic sequencing to establish and compare microbial profiles of the gut microbiota among different groups.

Structure and composition of oral microbiotaDay 1 after addmission due to the disease activity and signing an informed consent (for patients); or day 1 after signing an informed consent (for health controls)

DNA extraction from saliva samples will be tested through 16S microbial sequencing and metagenomic sequencing to establish and compare microbial profiles of the oral microbiota among different groups.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Peking Union Medical College Hospital

🇨🇳

Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath